QIAGEN Reports Third Quarter 2013 Results

                  QIAGEN Reports Third Quarter 2013 Results

PR Newswire

VENLO, The Netherlands, October 29, 2013

VENLO, The Netherlands, October 29, 2013 /PRNewswire/ --

  oQ3 2013 results: Adjusted net sales $323.8 million (+7% CER) on growth in
    all regions and customer classes; adjusted operating income $87.7 million;
    adjusted diluted EPS $0.28

  oMoving ahead in 2013 to accelerate innovation and growth across QIAGEN
    portfolio:

  oQIAsymphony breaks through 1,000 installed systems, driven by expansion of
    industry-leading menu that includes European launch of newartusCT/NG
    assay

  oNGS initiative building momentum, as acquisition of CLC bio and
    combination with Ingenuity build leadership in biological data analysis,
    interpretation and reporting

  oPersonalized Healthcare leadership strengthened with U.S. launch
    oftherascreenEGFR companion diagnostic and new pharma co-development
    projects

  oTop seven emerging markets deliver 23% CER growth in first nine months of
    2013

  oQIAGEN reaffirms guidance for higher adjusted sales and earnings in 2013

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of
operations for the third quarter and first nine months of 2013, delivering
sales growth in all regions and customer classes along with improved
profitability.

Adjusted net sales (including non-GAAP revenues from Ingenuity) in the third
quarter rose 6% from the year-ago quarter (+7% at constant exchange rates,
CER) to $323.8 million. Adjusted operating income in the quarter rose 5% to
$87.7 million, with the adjusted operating income margin at 27% of adjusted
net sales. Adjusted diluted earnings per share (EPS) rose to $0.28 in the
third quarter of 2013 from $0.26 in the same period of 2012.

"We are executing on strategic initiatives in 2013 to accelerate innovation
and growth by expanding QIAGEN's portfolio of new products. We exceeded our
communicated targets for improved sales and adjusted earnings in the third
quarter of 2013, delivering growth in all customer classes and regions,
particularly in emerging markets, under challenging economic conditions," said
Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. "Molecular Diagnostics
delivered double-digit sales growth, as the QIAsymphony automation platform
broke through 1,000 installed systems and we achieved further global expansion
of the QuantiFERON-TB latent tuberculosis test as well as our industry-leading
Personalized Healthcare franchise. The initiative to enter targeted areas of
next-generation sequencing is showing strong momentum, leveraging QIAGEN's
leadership in Sample & Assay Technologies to develop an ecosystem of universal
products and services for next-generation sequencing, as well as the
integrated, automated sample-to-insight GeneReader NGS benchtop workflow. The
acquisition of CLC bio, which offers leading bioinformatics analysis software,
reaffirms our strategic decision to become a leader in next-generation
bioinformatics, with a focus on biological analysis and
interpretation/reporting. With the capabilities, resources and employees to
continue our transformation despite a challenging macroeconomic environment,
QIAGEN continues to be well-positioned to achieve our goals for 2013 and to
create new drivers for future growth."

Thirdquarter 2013 results

                                                                     Change
    In $ millions, except per share
    information                                  Q3 2013  Q3 2012     $    CER
    Net sales, adjusted                            323.8    304.3    6%    7%
    Operating income, adjusted                      87.7     83.7    5%
    Net income, adjusted                            68.4     62.3   10%
    Diluted EPS, adjusted                          $0.28    $0.26
    For information on the adjusted figures, please refer to the
    reconciliation table accompanying this release. Adjusted net sales is
    a non-GAAP measure that includes all revenue contributions of
    Ingenuity following the acquisition on April 29, 2013. Due to
    purchase accounting rules, reported net sales is reduced by fair
    value adjustments to deferred revenue related to sales contracts
    executed by Ingenuity prior to the acquisition. Reconciliations of
    reported results in accordance with U.S. GAAP to adjusted results are
    included in the tables accompanying this release.

Adjusted net sales grew 7% at constant exchange rates (CER) in the third
quarter of 2013 on growth in all regions and customer classes. Total CER sales
growth was split evenly between the ongoing product portfolio and
contributions from Ingenuity Systems, Inc. (acquired April 29, 2013). Currency
movements had a negative impact of approximately one percentage point on
reported sales growth.

Operating income declined 12% to $34.4 million in the third quarter of 2013
from $39.0 million in the same period of 2012, with approximately $12.5
million of restructuring charges taken in the 2013 period for the final group
of projects in a major efficiency project being completed this year. Adjusted
operating income, which excludes items such as restructuring and
acquisition-related costs, share-based compensation and amortization of
intangible assets, rose 5% to $87.7 million from $83.7 million in year-ago
quarter. The adjusted operating income margin was 27.1% of adjusted net sales
in the third quarter of 2013 compared to 27.5% in the 2012 period.

Net income attributable to owners of QIAGEN N.V. rose 39% to $40.7 million, or
$0.17 per diluted share (based on 242.4 million shares), from $29.2 million,
or $0.12 per diluted share (based on 242.1 million shares) in the year-ago
period. Adjusted net income attributable to owners of QIAGEN N.V. rose 10% to
$68.4 million, which included currency gains, from $62.3 million in the
year-ago period. Adjusted diluted EPS rose to $0.28 per share compared to
$0.26 per share in the 2012 quarter.

"QIAGEN is well-positioned for a new growth wave that is taking shape with a
portfolio of innovative and differentiated products that address the needs of
our customers by transforming biological samples into valuable molecular
insights," said Roland Sackers, Chief Financial Officer of QIAGEN N.V. "We
have the financial resources to invest in attractive opportunities that create
value while also improving returns to shareholders, and the launch of our new
$100 million share repurchase program in the third quarter of 2013 is a signal
of that commitment. Our teams are determined to generate tangible benefits
from the recently completed efficiency program through faster growth,
improving profitability and higher cash flows. QIAGEN is on track to deliver
improved results in 2013 while building on a broad range of attractive growth
opportunities."

First nine months 2013 results

                                                                    Change
    In $ millions, except per share
    information                                  9M 2013  9M 2012    $    CER
    Net sales, adjusted                            943.7    907.9   4%     4%
    Operating income, adjusted                     249.5    250.4   0%
    Net income, adjusted                           187.3    177.9   5%
    Diluted EPS, adjusted                          $0.78    $0.74
    For information on the adjusted figures, please refer to the
    reconciliation table accompanying this release. Adjusted net sales is
    a non-GAAP measure that includes all revenue contributions of
    Ingenuity following the acquisition on April 29, 2013. Due to
    purchase accounting rules, reported net sales is reduced by fair
    value adjustments to deferred revenue related to sales contracts
    executed by Ingenuity prior to the acquisition. Reconciliations of
    reported results in accordance with U.S. GAAP to adjusted results are
    included in the tables accompanying this release.


Adjusted net sales rose 4% at constant exchange rates (CER) in the first nine
months of 2013 on growth in all regions and customer classes, particularly
Molecular Diagnostics (+8% CER), as higher sales of consumables and other
revenues (+6% CER) more than offset lower instrument sales (-4% CER). Total
sales growth of 4% CER was split evenly between the existing product portfolio
and the acquisitions of Ingenuity (acquired April 29, 2013) and AmniSure
International LLC (acquired May 3, 2012). Currency movements had no
significant impact on reported sales growth in the nine-month period.

Operating income in the first nine months of 2013 amounted to $29.3 million
compared to $120.9 million in the same period of 2012, due mainly to
restructuring charges of approximately $101.0 million related to a major
efficiency project completed in 2013. Adjusted operating income, which
excludes items such as restructuring and acquisition-related costs,
share-based compensation and amortization of intangible assets, was largely
unchanged at $249.5 million in the first nine months of 2013 compared to
$250.4 million in the 2012 period. The adjusted operating income margin
declined to 26.4% of adjusted net sales from 27.6% in the year-ago period.

In the first nine months of 2013, net income attributable to owners of QIAGEN
N.V. amounted to $8.9 million, or $0.04 per diluted share (based on 241.4
million shares), compared to net income of $91.1 million, or $0.38 per share
(based on 240.4 million shares), in the year-ago period. Adjusted net income
rose 5% to $187.3 million, or $0.78 per share on an adjusted diluted EPS
basis, from $177.9 million, or $0.74 per share in the 2012 period.

At September 30, 2013, cash and cash equivalents declined to $280.0 million
from $394.0 million at December 31, 2012. Net cash provided by operating
activities amounted to $176.8 million in the first nine months of 2013
compared to $175.0 million in the same period of 2012, with free cash flow
improving to $120.9 million compared to $107.0 million in the year-ago period.
Net cash used in investing activities was $237.1 million in the first nine
months of 2013, higher than the $222.7 million of net cash used in the same
period of 2012. Net cash used in financing activities was $49.8 million in the
first nine months of 2013, mainly due to completion of a share repurchase
program in March 2013 and launch of a subsequent share repurchase program,
compared to cash provided by financing activities of $81.6 million in the
year-ago period.

Business review

Geographic regions

In the third quarter of 2013, adjusted net sales in all regions advanced at
single-digit CER rates. The Americas (+8% CER, 50% of sales) advanced on
higher sales in Mexico, Brazil and the U.S., where sales growth more than
offset lower sales of HPV screening products. The Asia-Pacific / Japan region
(+7% CER, 19% of sales) was led by solid gains in China, India and Taiwan,
while sales in Japan were largely unchanged. The Europe / Middle East / Africa
region (+4% CER, 30% of sales) rose on improving results in Turkey, the Nordic
region, Germany and Italy. Sales in the top seven emerging markets (China,
Brazil, Turkey, Korea, India, Russia and Mexico) grew 38% CER and represented
15% of total sales, with double-digit gains in many key markets.

Product categories

In the third quarter of 2013, consumables and related revenues (+8% CER, 88%
of sales) rose across all customer classes, led by Molecular Diagnostics and
Applied Testing. Contributions from products in the Ingenuity portfolio
(recorded in this product category) also supported underlying sales growth in
Academia, Pharma and Molecular Diagnostics. For the first nine months of 2013,
consumables and related revenues were up 6% and represented 88% of sales.

Instruments (+0% CER, 12% of sales) were led by double-digit CER growth in
Molecular Diagnostics, supported by growing revenues from multi-year reagent
rental placements of the QIAsymphony automation system. Instrument sales were
also higher in Applied Testing, which has faced a tough comparison against
very strong results during 2012. Pharma and Academia sales of instruments were
lower compared to the year-ago period, mainly due to reduced funding for life
sciences research. For the first nine months of 2013, instrument sales
declined 4% and represented 12% of sales.

Customer classes

An overview of performance in QIAGEN's four customer classes (based on total
sales results including organic growth and acquisitions at CER):

Molecular Diagnostics (Q3 2013: +10% CER, 51% of adjusted net sales) delivered
double-digit CER growth in both consumables and instruments, backed by growing
sales of the QIAsymphony automation platform and QuantiFERON. In Prevention,
the QuantiFERON-TB test for detection of latent tuberculosis (TB) maintained a
growth pace of more than 20% CER, led by rapid penetration in the U.S. Sales
of products for HPV testing (+3% CER, 17% of total adjusted net sales)
continued to decline in the U.S. at the expected rate of approximately 10% CER
due to implementation of multi-year customer agreements in light of new
competitor pricing actions. Sales of products related to HPV were sharply
higher in the rest of the world. In Profiling, the growing base of installed
QIAsymphony platforms drove consumables sales growth at a double-digit CER
pace. Personalized Healthcare sales were mixed, with growth in sales of
companion diagnostic assays partially offset by timing-related significantly
lower revenues from co-development projects compared to the same period in
2012. In Point of Need, the AmniSure assay achieved results above its 20% CER
target growth rate. In the first nine months of 2013, Molecular Diagnostics
rose 8% CER and represented 50% of sales.

Applied Testing (Q3 2013: +6% CER, 8% of adjusted net sales) returned to
growth in the third quarter of 2013, with solid single-digit CER growth in
both consumables and instruments and most of the incremental gains coming from
the Asia-Pacific / Japan region. In the first nine months of 2013, Applied
Testing sales were up 2% CER and represented 8% of sales.

Pharma (Q3 2013: +3% CER, 19% of adjusted net sales) delivered improved
results as single-digit CER growth in consumables more than offset a
double-digit CER decline in instruments. All regions contributed to growth,
which also included first-time contributions from Ingenuity. In the first nine
months of 2013, Pharma sales were up 1% CER and represented 19% of sales.

Academia (Q3 2013: +2% CER, 22% of adjusted net sales) grew in all regions in
the third quarter of 2013 at single-digit CER rates, with improving
consumables sales but sharply lower instrument sales. The Asia-Pacific / Japan
region showed the strongest growth, led by China, while conditions remained
weak in the U.S. due to the ongoing U.S. government sequestration (which took
effect in March 2013) and cautious buying patterns ahead of the U.S.
government shutdown in October 2013. The first-time contributions from
Ingenuity added to the underlying sales performance, which was largely
unchanged compared to the third quarter of 2012. In the first nine months of
2013, Academia sales were flat and represented 23% of sales.

Accelerating innovation and growth in 2013

QIAGEN is accelerating the pace of innovation and growth in 2013 despite
challenging market conditions. Building on the progress of strategic
initiatives to leverage QIAGEN's leadership in Sample & Assay Technologies
across all customer classes, goals for 2013 focus on continuing to drive
platform success, adding test content for use in all customer classes and
broadening QIAGEN's geographic presence. Additional goals are to deliver
efficiency and effectiveness through resource allocation, improve QIAGEN's
position as an employer of choice and enhance customer experience.

Among recent developments in 2013:

  oQIAsymphony breaks through 1,000 placements and expands menu: QIAGEN has
    recently reached an important milestone in the success of its QIAsymphony
    automation platform, surpassing 1,000 cumulative placements during the
    third quarter of 2013. QIAsymphony is the industry's first modular
    sample-to-result system designed to run commercial assays as well as
    laboratory-developed tests. Building on the more than 750 placements at
    the end of 2012, demand remains strong for the QIAsymphony platform among
    customers in Molecular Diagnostics and the Life Sciences customer classes,
    driven by having the broadest range of tests available on a platform.
    Important new product launches are expanding the content menu on
    QIAsymphony, and QIAGEN has a portfolio of more than 35 assays in
    development. In Europe, QIAGEN launched the artus CT/NG QS-RGQ Kit, a test
    optimized for the detection of Chlamydia trachomatis (CT) and Neisseria
    gonorrhoeae (NG) infections. This new artus CT/NG QS-RGQ Kit for the
    QIAsymphony RGQ delivers a CE-IVD-compliant workflow that has been
    validated with vaginal, cervical and male urethral swabs and as well as
    with urine samples.
  oAddition of CLC bio builds leadership in biological analysis: QIAGEN
    recently acquired CLC bio, a global leader in bioinformatics software with
    a focus on next-generation sequencing (NGS). This acquisition enables
    QIAGEN to create a complete workflow from biological sample to valuable
    molecular insights. It strengthens QIAGEN's rapidly emerging portfolio of
    "universal" products that can be used with any NGS sequencer as well as
    providing a key element to the portfolio of automated solutions for the
    GeneReader™ benchtop NGS sequencer workflow, which is currently in
    late-stage development. CLC bio, a privately-held company based in Aarhus,
    Denmark, was founded in 2005 and has created the leading commercial data
    analysis solutions and workbenches for NGS. It serves leading research
    institutions and top pharmaceutical companies worldwide. CLC bio's
    products are used as an integrating workbench to handle biological data
    generated by a sequencer through a series of analysis stages. The addition
    of this portfolio follows QIAGEN's recent acquisition of Ingenuity
    Systems, Inc., the market leader in solutions for handling biological data
    through the interpretation and reporting stages. CLC bio's leading
    products are CLC Genomics Workbench, a comprehensive and user-friendly
    analysis package for analyzing, comparing and visualizing NGS data; and
    CLC Genomics Server, a flexible enterprise-level infrastructure and
    analysis backbone for NGS data analysis. The "cross-platform" systems
    offered by CLC bio support all major NGS platforms. QIAGEN intends to
    offer client/server- based solutions using CLC bio products for the
    GeneReader system. Financial terms of the transaction were not disclosed.
    QIAGEN does not expect CLC bio to have a material financial impact on its
    results for 2013.
  oExpanding leadership in biological interpretation and reporting: The rapid
    adoption of Ingenuity^® Variant Analysis™, a market-leading solution based
    on the Ingenuity Knowledge Base, is solidifying the position of QIAGEN as
    the leader in the rapidly growing area of biological data interpretation
    and reporting. More than 4,000 users representing over 500 leading
    institutions already have adopted this solution as part of the rapid
    uptake in clinical areas. Interpretation of raw biological data is
    considered one of the most significant challenges in NGS applications, and
    QIAGEN's Ingenuity portfolio provides powerful solutions to address this
    bottleneck. Among the new customers is the Genetic Testing Laboratory at
    the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai in
    New York, which has adopted Ingenuity Variant Analysis for research and
    translational genomics applications related to characterizing and
    identifying rare diseases. QIAGEN has also announced a new collaboration
    with the Center for Applied Genomics at the Children's Hospital of
    Philadelphia involving a large-scale NGS study to identify causal variants
    in rare childhood diseases.
  oNGS initiative from biological sample to valuable molecular insights:
    QIAGEN is delivering on a strategic initiative to create an
    industry-leading portfolio of products and services to drive the adoption
    of next-generation sequencing (NGS) in clinical research and diagnostics.
    QIAGEN is creating differentiated solutions for workflow challenges. These
    solutions can accelerate the adoption of NGS in these targeted areas,
    particularly through improved automation compared to current systems to
    generate sequencing data as well as through the acceleration of data
    analysis and interpretation. Key elements include developing and
    commercializing an innovative sample-to-insight workflow incorporating the
    GeneReader™ benchtop NGS sequencer with the QIAcube and QIAcube NGS
    instruments for full automation of pre-analytical steps, and also
    integrating the market-leading biological data analysis, interpretation
    and reporting capabilities provided by CLC bio and Ingenuity. QIAGEN has
    placed the system with select customers for early testing, and initiatives
    are underway for a phased launch to select customer groups and broad
    commercialization in 2014. Another key element is commercializing
    "universal" solutions that are compatible with any NGS platform on the
    market and functional in a wide range of applications. Products launched
    to date include several pre-analytic kits, including the REPLI-g Single
    Cell Kit that enables sequencing from single cells and minute amounts of
    DNA with highly accurate results, and an expanding portfolio of GeneRead^™
    DNAseq gene panels for enrichment of targeted DNA regions, which are
    aligned with interpretation based on Ingenuity Variant Analysis. The
    current portfolio of nine cancer-focused gene panels is being expanded to
    20 gene panels for use in cancer and other areas, including inherited
    diseases and cardiovascular conditions.
  oPersonalized Healthcare leadership with new products and collaborations:
    QIAGEN is advancing its global leadership in companion diagnostics, which
    are used by physicians to guide treatment decisions, through new product
    launches as well as new co-development agreements with leading
    pharmaceutical companies. In July, the U.S. Food and Drug Administration
    (FDA) approved the therascreen EGFR RGQ PCR Kit as a companion diagnostic
    to guide the use of the new targeted therapy Gilotrif^® (afatinib) from
    Boehringer Ingelheim, which received FDA approval for use in metastatic
    non-small cell lung cancer (NSCLC) patients. Discussions with healthcare
    payers in the U.S. have been very positive, with reimbursement levels
    reflecting the value of this test in improving healthcare outcomes for
    patients. The EGFR approval follows the 2012 U.S. launch of the
    therascreen KRAS RGQ PCR Kit paired for use with Erbitux^® (cetuximab)
    from Eli Lilly and Bristol-Myers Squibb for metastatic colorectal cancer
    patients. QIAGEN has been expanding its portfolio of co-development
    projects with agreements that include partnership extensions as well as
    new projects with pharmaceutical companies. In one of the new
    partnerships, which was announced on October 21, QIAGEN and Clovis
    Oncology (NASDAQ: CLVS) have entered into a framework agreement to
    co-develop and co-commercialize a companion diagnostic test to guide the
    use of CO-1686, which is currently in clinical development and targets an
    unmet clinical need in patients with epidermal growth factor receptor
    (EGFR) driven non-small cell lung cancer (NSCLC) for whom current
    EGFR-inhibiting drugs no longer control disease.

New $100 million share repurchase program underway

QIAGEN launched its second $100 million share repurchase program in early
September. The first $10 million tranche was completed in early October with
the repurchase of 483,576 shares on the Frankfurt Stock Exchange at a
volume-weighted average price of EUR 15.62. Repurchased shares will be held in
treasury in order to satisfy obligations for exchangeable debt instruments and
employee share-based remuneration plans. Information on the progress of the
program is available in the Investor Relations section of QIAGEN's website at
http://www.qiagen.com.

2013 outlook

QIAGEN continues to expect to deliver improved results for full-year 2013,
with expected adjusted net sales growth of approximately 5% CER and adjusted
diluted EPS of approximately $1.13. Full-year reported sales are expected to
be adversely affected by currency movements during the year against the U.S.
dollar, QIAGEN's reporting currency. For the fourth quarter of 2013, QIAGEN
expects adjusted net sales growth of approximately 6% CER and adjusted diluted
EPS of approximately $0.35. The full-year 2013 expectations reaffirm the
previous guidance provided on July 30, 2013, and do not take into account
further acquisitions that could be completed this year.

Conference call and webcast details

Information on QIAGEN's performance will be presented during a conference call
on Wednesday, October 30, 2013, at 9:30 ET / 13:30 GMT / 14:30 CET (European
times adjusted for the end of European Daylight Savings Time.) The
corresponding presentation slides will be available for download shortly
before the event at
http://www.qiagen.com/About-Us/Investors/Events-and-Presentations/Conference-Calls,
and a webcast will be available at this website. A replay will also be made
available on this website.

Use of adjusted results

QIAGEN has regularly reported adjusted results, as well as results considered
on a constant exchange rate basis, to give additional insight into its
financial performance. These adjusted results include adjusted net sales,
adjusted gross profit, adjusted operating income, adjusted net income
attributable to owners of QIAGEN N.V., adjusted diluted EPS and free cash
flow. Adjusted results are non-GAAP financial measures that QIAGEN believes
should be considered in addition to the reported results prepared in
accordance with generally accepted accounting principles, but should not be
considered as a substitute. Free cash flow is calculated by deducting capital
expenditures for Property, Plant & Equipment from cash flow from operating
activities. QIAGEN believes certain items should be excluded from adjusted
results when they are outside of its ongoing core operations, vary
significantly from period to period, or affect the comparability of results
with its competitors and its own prior periods. Reconciliations of reported
results to adjusted results are included in the tables accompanying this
release.

As of January 1, 2014, QIAGEN will implement two changes to its presentation
of adjusted results. First, share-based compensation will be included as a
cost in adjusted results, and information on share-based compensation will
continue to be disclosed in QIAGEN's regulatory filings and annual reports.
Furthermore, also as of January 1, 2014, with the completion of the efficiency
project in 2013, costs for restructuring will only be adjusted for those
related to business integration and acquisition-related activities.

Press release and tables with detailed financial information can be downloaded
in PDF format at http://www.qiagen.com/about-us/press-releases/.

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global provider
ofSample& AssayTechnologies that are used to transform biological materials
into valuable molecular information. Sample technologies are used to isolate
and process DNA, RNA and proteins from biological samples such as blood or
tissue. Assay technologies arethen used to make these isolated biomolecules
visible and ready for interpretation. QIAGENmarkets more than 500
productsaround the world, selling both consumable kits and automation systems
to customers through four customer classes: Molecular Diagnostics (human
healthcare), Applied Testing (forensics, veterinary testing and food safety),
Pharma (pharmaceutical and biotechnology companies) and Academia (life
sciences research).As of September 30, 2013, QIAGEN employed more than 4,100
people in over 35 locations worldwide. Further information can be found at
http://www.qiagen.com.

Certain of the statements contained in this news release may be considered
forward-looking statements within the meaning of Section 27A of the U.S.
Securities Act of 1933, as amended, and Section 21E of the U.S. Securities
Exchange Act of 1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, markets, strategy or operating
results, including without limitation its expected operating results, new
product developments, new product launches, regulatory submissions, and
financing plans are forward-looking, such statements are based on current
expectations and assumptions that involve a number of uncertainties and risks.
Such uncertainties and risks include, but are not limited to, risks associated
with management of growth and international operations (including the effects
of currency fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer classes, the
commercial development of markets for our products in applied testing,
personalized healthcare, clinical research, proteomics, women's health/HPV
testing and nucleic acid-based molecular diagnostics; changing relationships
with customers, suppliers and strategic partners; competition; rapid or
unexpected changes in technologies; fluctuations in demand for QIAGEN's
products (including fluctuations due to general economic conditions, the level
and timing of customers' funding, budgets and other factors); our ability to
obtain regulatory approval of our products; difficulties in successfully
adapting QIAGEN's products to integrated solutions and producing such
products; the ability of QIAGEN to identify and develop new products and to
differentiate and protect our products from competitors' products; market
acceptance of QIAGEN's new products, the consummation of acquisitions, and the
integration of acquired technologies and businesses. For further information,
please refer to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission (SEC).

Contacts

Public Relations:
Dr. Thomas Theuringer
Director Public Relations
+49-2103-29-11826
+1-240-686-7425

Email: pr@qiagen.com

http://www.twitter.com/qiagen

http://www.qiagen.com/About-Us/Press-and-Media/

Investor Relations:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
+1-240-686-2222

Email: ir@qiagen.com

http://www.qiagen.com/About-Us/Investors/

SOURCE Qiagen N.V.
 
Press spacebar to pause and continue. Press esc to stop.